## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1-26. **(Canceled)**

27. **(Currently Amended)** A method of increasing an immune response in a subject comprising administering to the subject a first cell transformed to express on its surface an antibody or antibody binding fragment thereof linked to a transmembrane protein domain from platelet derived growth factor receptor, wherein the antibody or antibody fragment ~~which~~ binds to an Fc receptor of an effector cell~~, wherein the binding to the Fc receptor~~ and induces phagocytosis and lysis of the first cell, and wherein the binding to the FcR is not blocked by endogenous ligand.

28. **(Original)** The method of claim 27 further comprising administering to the subject an agent that increases expression of Fc receptors on effector cells.

29. **(Original)** The method of claim 28, wherein the agent is a cytokine.

30. **(Original)** The method of claim 29, wherein the cytokine is selected from the group consisting of G-CSF, GM-CSF, IFN-γ, TNF, and combinations thereof.

31. **(Previously Presented)** The method of claim 27, wherein the first cell is a tumor cell.

32. **(Previously Presented)** The method of claim 27, wherein the first cell is transformed ex vivo, and then administered to the subject.

33. **(Currently Amended)** A method of increasing an immune response to an antigen, comprising

(a) transforming *ex vivo* a first cell which expresses the antigen with a nucleic acid encoding an antibody or fragment thereof linked to a transmembrane protein domain from platelet derived growth factor receptor, wherein the antibody or antibody fragment ~~which~~ binds to an Fc receptor on an effector cell~~, wherein the binding to the Fc receptor~~ and induces phagocytosis and lysis of the cell, wherein the binding to the FcR is not blocked by the endogenous ligand; and

(b) contacting the cell *in vivo* with an effector cell in the presence of a lymphocyte.

34-35. **(Canceled)**

36. **(Original)** The method of claim 33, wherein the antibody comprises antibody H22 having ATCC number CRL 11,177, or antibody A77.

37. **(Original)** The method of claim 36, wherein the antibody fragment comprises a single chain Fv fragment of H22 or A77.

38. **(Original)** The method of claim 33, wherein the nucleic acid encodes a fusion protein comprising an antibody or antibody fragment and a transmembrane protein.

39. **(Original)** The method of claim 33, wherein the antigen is selected from the group consisting of a tumor antigen and a component of a pathogen.

40-48. **(Canceled)**

49. **(Previously Presented)** The method of claim 27, wherein the antibody fragment is a single chain Fv fragment.

50. **(Previously Presented)** The method of claim 33, wherein the antibody fragment is a single chain Fv fragment.

51. **(Previously Presented)** The method of claim 27, wherein the antibody is selected from the group consisting of an IgA, an IgG and fragments thereof.

52. **(Previously Presented)** The method of claim 33, wherein the antibody is selected from the group consisting of an IgA, an IgG and fragments thereof.

53. **(Previously Presented)** The method of claim 27, wherein the antibody or antibody fragment which binds to the Fc receptor is produced recombinantly in the cell.

54. **(Previously Presented)** The method of claim 27, wherein binding of the antibody to the Fc receptor is not blocked by IgA or IgG.

55. **(Previously Presented)** The method of claim 33, wherein binding of the antibody to the Fc receptor is not blocked by IgA or IgG.

56. **(Previously Presented)** The method of claim 27, wherein the Fc receptor is selected from the group consisting of an Fcγ receptor, an Fcα receptor, an Fcμ receptor, and an Fcε receptor.

57. **(Previously Presented)** The method of claim 33, wherein the Fc receptor is selected from the group consisting of an Fcγ receptor, an Fcα receptor, an Fcμ receptor, and an Fcε receptor.

58. **(Previously Presented)** The method of claim 27, wherein the Fc receptor is selected from the group consisting, of FcγI, FcγII, and FcγIII.

59. **(Previously Presented)** The method of claim 33, wherein the Fc receptor is selected from the group consisting, of FcγI, FcγII, and FcγIII.

60. **(Previously Presented)** The method of claim 39, wherein the tumor antigen is selected from the group consisting of HER-2/neu, TAG 72, carcinoembryonic antigen, and gastrin releasing peptide.

61. **(Previously Presented)** The method of claim 27, wherein the first cell is a mammalian cell.

62. **(Previously Presented)** The method of claim 33, wherein the first cell is a mammalian cell.